FreeQAs
 Request Exam  Contact
  • Home
  • View All Exams
  • New QA's
  • Upload
PRACTICE EXAMS:
  • Oracle
  • Fortinet
  • Juniper
  • Microsoft
  • Cisco
  • Citrix
  • CompTIA
  • VMware
  • ISC
  • SAP
  • EMC
  • PMI
  • HP
  • Salesforce
  • Other
  • Oracle
    Oracle
  • Fortinet
    Fortinet
  • Juniper
    Juniper
  • Microsoft
    Microsoft
  • Cisco
    Cisco
  • Citrix
    Citrix
  • CompTIA
    CompTIA
  • VMware
    VMware
  • ISC
    ISC
  • SAP
    SAP
  • EMC
    EMC
  • PMI
    PMI
  • HP
    HP
  • Salesforce
    Salesforce
  1. Home
  2. SCDM Certification
  3. CCDM Exam
  4. SCDM.CCDM.v2026-02-03.q51 Dumps
  • ««
  • «
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • »
Download Now

Question 31

Data characterizing the safety profile of a drug are collected to provide information for which of the following?

Correct Answer: C
Safety data collected during a clinical trial are used primarily to support product labeling, ensuring accurate communication of a drug's risks, contraindications, and adverse reactions to healthcare providers and patients.
According to the GCDMP (Chapter: Safety Data Handling and Reconciliation) and ICH E2A/E2F guidelines, all adverse events (AEs), serious adverse events (SAEs), and laboratory abnormalities are analyzed and summarized to define the safety profile of an investigational product. These data form the basis for regulatory submissions such as the Clinical Study Report (CSR) and product labeling (e.g., prescribing information), as required by the FDA and other regulatory authorities.
While safety data may contribute indirectly to analyses such as survival curves (option A) or quality of life metrics (option D), their primary regulatory function is to inform product labeling and post-marketing surveillance documentation.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Safety Data Handling and Reconciliation, Section 4.3 - Use of Safety Data in Regulatory Submissions ICH E2A - Clinical Safety Data Management: Definitions and Standards for Expedited Reporting FDA Guidance for Industry: Adverse Event Reporting and Labeling Requirements
insert code

Question 32

A protocol amendment adds three data elements to the vital signs screen and two additional data-collection time points. Which is best practice for handling changes to the form completion guidelines?

Correct Answer: A
The best practice when implementing a protocol amendment that affects CRF content or data collection timing is to update the eCRF completion guidelines and notify sites before implementing the change.
According to the GCDMP (Chapter: CRF Design and Data Collection), the eCRF Completion Guidelines (eCRF CG) are an essential study tool that instructs site personnel on accurate and consistent data entry. When new data elements or collection time points are added, the guidelines must be revised, version-controlled, and communicated to all users prior to implementation to ensure sites collect and enter data correctly.
Simply relying on the revised CRF (option C) or updating the document without notification (option B) violates communication and training standards. Likewise, notifying sites without updating the documentation (option D) leaves insufficient reference material for data entry compliance.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: CRF Design and Data Collection, Section 5.5 - Managing CRF Revisions and Site Communication ICH E6 (R2) GCP, Section 5.18.4 - Communication of Protocol Amendments and Documentation Updates FDA Guidance for Industry: Electronic Source Data in Clinical Investigations, Section 4.3 - Site Communication and Documentation Management
insert code

Question 33

Which statement applies to the CRF Completion Guidelines (CCGs) for a multinational study?

Correct Answer: B
The Case Report Form (CRF) Completion Guidelines (CCGs) are critical documents that guide site staff on how to accurately and consistently record data on CRFs across all participating sites, especially in multinational trials.
According to the Good Clinical Data Management Practices (GCDMP, Chapter: CRF Design and Data Collection), one of the key components of the CCGs is a list of acceptable abbreviations and conventions to be used during CRF entry. This standardization ensures data consistency across languages and countries, reduces ambiguity during data review, and facilitates database design and coding accuracy.
While translation (A) may be useful for training materials, it is not required for CCGs unless specified by regulatory bodies. Options C and D are incorrect because data collection should adhere to standardized terms in English (or the study's official language) - allowing free use of local languages or arbitrary abbreviations introduces inconsistencies.
Hence, option B - "CCGs must contain the list of acceptable abbreviations to be used in the CRF" - is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: CRF Design and Data Collection, Section 5.3 - CRF Completion Guidelines and Standardization ICH E6(R2) GCP, Section 5.5.3 - Consistency and Data Recording Requirements FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.2 - Data Entry Conventions and Documentation
insert code

Question 34

What is the purpose of providing the central laboratory vendor with a complete listing of subjects' demographic data?

Correct Answer: C
Providing the central laboratory vendor with a complete subject demographic listing allows ongoing reconciliation between the sponsor's EDC system and the vendor's laboratory database during study conduct.
The GCDMP (Chapter: External Data Transfers and Integration) emphasizes that subject reconciliation ensures that all laboratory data correspond to valid enrolled subjects and visits. Regular reconciliation throughout the study prevents data mismatches, missing results, or misassigned lab reports.
This proactive measure supports timely query resolution and data integrity across systems. Waiting until after database lock (as in option A) would delay corrections and risk inconsistencies. Options B and D address secondary benefits but not the primary purpose-ongoing subject-level reconciliation.
Thus, option C is correct.
Reference (CCDM-Verified Sources):
SCDM GCDMP, Chapter: External Data Transfers, Section 4.4 - Reconciliation and Vendor Communication ICH E6(R2) GCP, Section 5.5.3 - Data Management, Reconciliation, and Integration FDA Guidance for Industry: Computerized Systems Used in Clinical Investigations, Section 6.3 - External Data Management
insert code

Question 35

A Clinical Data Manager reads a protocol for a clinical trial to test the efficacy of an antiviral to counteract a new epidemic. The stated primary efficacy endpoint is 3-month survival. Which data element is needed for the primary efficacy endpoint?

Correct Answer: A
When the primary efficacy endpoint in a clinical trial is 3-month survival, the key data element required is the death date. This is because the survival endpoint is determined by calculating whether the subject lived or died within a defined time frame from study enrollment or randomization.
According to the GCDMP (Chapter: Data Management Planning and Study Start-up), the Clinical Data Manager (CDM) must identify and ensure the capture of all critical data elements necessary to evaluate the study endpoints. For time-to-event analyses (e.g., survival studies), accurate event dates (death date) are essential for endpoint derivation and statistical analysis.
Other data elements such as cause of death or date of autopsy (options B and C) may support secondary analyses or safety reviews but are not necessary to determine the survival endpoint itself. Similarly, birth date (option D) contributes to demographic data but is unrelated to the primary efficacy outcome.
Reference (CCDM-Verified Sources):
SCDM Good Clinical Data Management Practices (GCDMP), Chapter: Data Management Planning and Study Start-up, Section 4.4 - Critical Data Identification for Endpoints ICH E9 - Statistical Principles for Clinical Trials, Section 2.2.3 - Time-to-Event Data Considerations FDA Guidance for Industry: Clinical Trial Endpoints for Drug Development
insert code
  • ««
  • «
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • »
[×]

Download PDF File

Enter your email address to download SCDM.CCDM.v2026-02-03.q51 Dumps

Email:

FreeQAs

Our website provides the Largest and the most Latest vendors Certification Exam materials around the world.

Using dumps we provide to Pass the Exam, we has the Valid Dumps with passing guranteed just which you need.

  • DMCA
  • About
  • Contact Us
  • Privacy Policy
  • Terms & Conditions
©2026 FreeQAs

www.freeqas.com materials do not contain actual questions and answers from Cisco's certification exams.